United Services Automobile Association Buys 15,908 Shares of DexCom, Inc. (DXCM)

Share on StockTwits

United Services Automobile Association lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 36.4% during the 2nd quarter, Holdings Channel reports. The firm owned 59,636 shares of the medical device company’s stock after purchasing an additional 15,908 shares during the quarter. United Services Automobile Association’s holdings in DexCom were worth $5,664,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. State Board of Administration of Florida Retirement System lifted its holdings in DexCom by 0.4% in the second quarter. State Board of Administration of Florida Retirement System now owns 120,747 shares of the medical device company’s stock valued at $11,469,000 after acquiring an additional 470 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in DexCom by 9.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,552 shares of the medical device company’s stock valued at $527,000 after acquiring an additional 471 shares during the last quarter. Metropolitan Life Insurance Co. NY lifted its holdings in DexCom by 7.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 6,879 shares of the medical device company’s stock valued at $653,000 after acquiring an additional 486 shares during the last quarter. Xact Kapitalforvaltning AB lifted its holdings in DexCom by 4.1% in the second quarter. Xact Kapitalforvaltning AB now owns 12,700 shares of the medical device company’s stock valued at $1,206,000 after acquiring an additional 500 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in DexCom by 11.9% in the first quarter. PNC Financial Services Group Inc. now owns 5,943 shares of the medical device company’s stock valued at $440,000 after acquiring an additional 634 shares during the last quarter.

In other DexCom news, SVP Patrick Michael Murphy sold 400 shares of the company’s stock in a transaction on Wednesday, October 10th. The stock was sold at an average price of $122.20, for a total transaction of $48,880.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Andrew K. Balo sold 5,000 shares of the company’s stock in a transaction on Friday, September 14th. The stock was sold at an average price of $145.17, for a total value of $725,850.00. The disclosure for this sale can be found here. Insiders have sold 201,104 shares of company stock worth $26,507,570 over the last 90 days. 1.80% of the stock is owned by insiders.

NASDAQ:DXCM opened at $127.07 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.62 and a current ratio of 4.89. DexCom, Inc. has a 52 week low of $43.74 and a 52 week high of $148.56. The firm has a market cap of $12.64 billion, a price-to-earnings ratio of -214.42 and a beta of 0.47.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Wednesday, August 1st. The medical device company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.08. DexCom had a negative return on equity of 7.45% and a negative net margin of 0.65%. The company had revenue of $242.50 million for the quarter, compared to analysts’ expectations of $205.81 million. During the same period in the prior year, the firm earned ($0.16) earnings per share. The firm’s revenue was up 42.1% compared to the same quarter last year. As a group, analysts anticipate that DexCom, Inc. will post -0.47 EPS for the current fiscal year.

A number of research analysts recently commented on DXCM shares. Northland Securities upgraded DexCom from an “under perform” rating to a “market perform” rating in a report on Wednesday, September 12th. Raymond James upgraded DexCom from a “market perform” rating to an “outperform” rating in a report on Monday, July 2nd. BidaskClub upgraded DexCom from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 21st. BMO Capital Markets upped their price objective on DexCom to $112.00 and gave the company an “outperform” rating in a report on Tuesday, July 10th. Finally, Stephens upped their price objective on DexCom from $135.00 to $160.00 and gave the company an “overweight” rating in a report on Thursday, August 23rd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. DexCom currently has an average rating of “Buy” and an average price target of $123.13.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Story: Dow Jones Industrial Average (DJIA)

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply